IDEMIA Trials Biometric Verification Program with Royal Caribbean Cruises Ltd. and U.S. Customs and Border Protection
IDEMIA, the global leader in trusted identities for an increasingly digital world and the country’s preeminent identity-related service provider, and Royal Caribbean Cruises Ltd. (RCL) jointly announced today they have completed a trial with U.S. Customs and Border Protection (CBP) using facial recognition to validate passengers’ identities for entry and re-entry of cruise ships to further secure and expedite passenger processing at U.S. sea-ports of entry.
A “Sea Re-entry” trial, conducted at Cape Liberty Cruise Port in New Jersey, utilized IDEMIA’s facial capture and recognition solution to confirm the facial identities of individuals disembarking Royal Caribbean ships with the facial identities of ticketed passengers who boarded the ship at the start of a cruise. The trial demonstrated high quality/high speed facial matching with large passenger populations, expedited Customs egress and confirmation that individuals embarking the ship are the same as those disembarking. Surveys of disembarking passengers showed high degrees of satisfaction regarding speed of clearing customs and intuitive engagement with the facial camera.
RCL, IDEMIA and CBP jointly viewed the Sea Re-entry trials as a strong example of public-private partnership. “IDEMIA is at the forefront of the ‘Passenger Transformation’”, said Bob Eckel, President of IDEMIA North America. “Passengers need to move safely, but also fast and conveniently through the border processes. The biometric solutions we are testing with RCL and CBP allow us to demonstrate the important technology that can be used in border management applications today in an efficient and safe manner. Facial recognition in particular is a non-intrusive way to easily and securely facilitate U.S. and non-U.S. citizens entering and exiting the country, an initiative important to the Federal government.”
Captain Thomas Hinderhofer of RCL and Director of Cape Liberty Port Operations states: “Royal Caribbean’s commitment to providing our guests a pleasurable experience includes making the final step of clearing customs fast, secure and frictionless. The trial exceeded our expectations in terms of being able to quickly process passengers re-entering the country while at the same time addressing key border management requirements.”
# # #
OT-Morpho is now IDEMIA, the global leader in trusted identities for an increasingly digital world, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to €3bn in revenues, IDEMIA is the result of the coming together of OT (Oberthur Technologies) and Safran Identity & Security (Morpho). This new company counts 14,000 employees of more than 80 nationalities and serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
CA-TRADESHIFT19.10.2018 13:02 | pressemeddelelse
Tradeshift Announces Q3 2018 Results
ALIBABA-GROUP19.10.2018 12:17 | pressemeddelelse
Alibaba’s Robust Ecosystem Supercharges 2018 11.11 Global Shopping Festival
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum